● pepmg Research Desk · Peer-reviewed evidence review
What the research says about cagrilintide
A neutral summary of the peer-reviewed literature on cagrilintide, an investigational long-acting amylin analogue studied in an early-phase human trial for weight management. Research use only.
Moderate evidence — Limited human trials — often early-phase. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Cagrilintide is an investigational long-acting amylin analogue studied for weight management; the main standalone human data is a phase 2, dose-finding randomized trial [1][3].
- That phase 2 trial reported mean weight reductions of about 6.0% to 10.8% across cagrilintide doses versus 3.0% on placebo over 26 weeks [1].
- A later phase 3 trial studied cagrilintide combined with semaglutide (CagriSema), not cagrilintide alone [2]; as of this review cagrilintide is not an approved medicine.
- This page reports what the trials measured and links to each — it is not medical advice, an efficacy or safety claim, or dosing guidance.
What cagrilintide is
Cagrilintide is described in the literature as a stable, lipidated long-acting amylin analogue — amylin being a pancreatic hormone that induces satiety [1][3]. A medicinal-chemistry paper documents the structure-activity work that led to selecting cagrilintide for clinical development in obesity [3].
Cagrilintide is investigational and not approved. It is often discussed alongside its combination with semaglutide (known as CagriSema), but the two should not be conflated: most of the standalone human evidence for cagrilintide by itself is early-phase [1][2].
What the human research has measured
Moderate evidenceThe main standalone human study is a phase 2, randomized, double-blind, placebo- and active-controlled dose-finding trial in 706 participants with overweight or obesity, run over 26 weeks [1]. It reported mean body-weight reductions from baseline of about 6.0% to 10.8% across the cagrilintide dose groups (0.3–4.5 mg) versus 3.0% on placebo, and that the highest dose reported a slightly greater reduction than the active comparator liraglutide 3.0 mg [1]. The most frequent adverse events reported were gastrointestinal, chiefly nausea [1].
A larger phase 3a trial (REDEFINE 1) enrolled 3,417 adults but studied the combination of cagrilintide and semaglutide (CagriSema) against placebo, not cagrilintide alone [2]. It reported a mean body-weight change of about −20.4% with the combination versus −3.0% with placebo over 68 weeks [2]. Because this measured a two-drug combination, it does not by itself establish what cagrilintide does on its own.
Taken together, cagrilintide's standalone human evidence is early-phase (a single phase 2 dose-finding trial), which is why this review is characterized as moderate rather than strong or preclinical [1][2][3].
How strong is the evidence
Randomized human data exists for cagrilintide, which is why this review is moderate rather than preclinical — but the standalone evidence is a single early-phase (phase 2) trial, and the larger phase 3 program to date studied a combination product rather than the compound alone [1][2]. "Moderate" describes that early-but-real human evidence base, not a claim that cagrilintide works or is safe.
Nothing here is dosing, medical, or safety guidance. Read the trials themselves and consult a qualified professional — this page is a map to the evidence, not a recommendation.
Sources · 3
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
- Development of Cagrilintide, a Long-Acting Amylin Analogue.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.